An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)
Study Treatment (INO-5401 and INO-9012 delivered by electoporation device in combination with REGN2810) in Subjects with Glioblastoma
Sponsor: Inovio Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR8166
U.S. Govt. ID: NCT03491683
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this clinical study is to evaluate safety of the study treatment, its effects on the immune system and on GBM. The study treatment includes several experimental therapies: INO-5401 + INO-9012 delivered by an electroporation device called CELLECTRA 2000 used for delivery of INO-5401 + INO-9012 into your muscle. You will also receive another experimental study treatment called REGN2810 (also called cemiplimab).
This study is closed
Investigator
Mary Welch, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have newly diagnosed glioblastoma? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE